0001104659-23-108762.txt : 20231012 0001104659-23-108762.hdr.sgml : 20231012 20231012122220 ACCESSION NUMBER: 0001104659-23-108762 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20231012 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231012 DATE AS OF CHANGE: 20231012 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Edesa Biotech, Inc. CENTRAL INDEX KEY: 0001540159 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37619 FILM NUMBER: 231322175 BUSINESS ADDRESS: STREET 1: 100 SPY COURT CITY: MARKHAM STATE: A6 ZIP: L3R 5H6 BUSINESS PHONE: (905) 475-1234 MAIL ADDRESS: STREET 1: 100 SPY COURT CITY: MARKHAM STATE: A6 ZIP: L3R 5H6 FORMER COMPANY: FORMER CONFORMED NAME: Stellar Biotechnologies, Inc. DATE OF NAME CHANGE: 20120120 8-K 1 tm2328265d1_8k.htm FORM 8-K
0001540159 false 00-0000000 0001540159 2023-10-12 2023-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 12, 2023

 

Edesa Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

British Columbia, Canada   001-37619   N/A
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)
     
100 Spy Court
Markham, Ontario, Canada L3R 5H6
(Address of Principal Executive Offices)

 

(289) 800-9600

Registrant’s telephone number, including area code

 

N/A

 (Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Shares   EDSA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On October 12, 2023, Edesa Biotech Research, Inc. (“Edesa Biotech Research”), a wholly owned subsidiary of Edesa Biotech, Inc. (the “Company”) and the Company, as guarantor, entered into a multi-year contribution agreement (the “Agreement”) with the Government of Canada. Pursuant to the Agreement, the Government of Canada committed up to CAD $23 million ($17 million USD) in partially repayable funding toward (i) conducting and completing the Company’s Phase 3 clinical study of its experimental drug EB05 (paridiprubart) in critical-care patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 or other infectious agents, (ii) submitting EB05 for governmental approvals and manufacturing scale-up, following, and subject to, completing the Phase 3 study and (iii) conducting two non-clinical safety studies to assess the potential long-term impact of EB05 exposure (the “Project”). Edesa Biotech Research agreed to complete the Project, which will be conducted exclusively in Canada (except as permitted otherwise under certain circumstances), on or before December 31, 2025. The Company agreed to guarantee the complete performance and fulfillment of Edesa Biotech Research’s obligations under the Agreement. In the event Edesa Biotech Research fails to perform or otherwise satisfy any of its obligations related to the Agreement, the Company will become a primary obligor under the Agreement.

 

Of the CAD $23 million committed by the Government of Canada under the Agreement, CAD $5.75 million is not repayable. The remaining CAD $17.25 million is conditionally repayable starting in 2029 only if and when the Company earns gross revenue. The repayable portion would be payable over fifteen (15) years based on a percentage rate of the Company’s annual revenue growth. The maximum amount repayable under the Agreement is 1.4 times the original repayable amount. In addition, the Company is entitled to partial reimbursement of certain eligible expenses under the Agreement.

 

Under the Agreement, Edesa Biotech Research has agreed to certain financial and non-financial covenants and other obligations in relation to the Project, including (i) the achievement of certain headcount requirements in Canada, (ii) the maintenance of a collaboration with a Canadian research institute or post-secondary institutions, (iii) the maintenance of certain research and development expenditures in Canada, (iv) the maintenance of inclusive hiring practices and employee training and (v) the creation of an environmental sustainability plan. In addition, Edesa Biotech Research has granted notice and consent rights to the Government of Canada upon certain events related to a Change in Control (as defined in the Agreement).

 

For the term of the Agreement, Edesa Biotech Research must have exclusive ownership of all intellectual property (i) conceived, produced or developed in connection with the Project and (ii) that is required for the carrying out of the Project (the “Intellectual Property”). Pursuant to the Agreement, Edesa Biotech Research is required, subject to certain exceptions, to obtain the consent of the Government of Canada prior to granting any right or license to any of the Intellectual Property. Furthermore, the Government of Canada may require Edesa Biotech Research to assign, transfer or grant a license to use the Intellectual Property to the extent necessary to ensure a sufficient domestically-sourced supply of vaccines and/or treatments in response to COVID-19 if Edesa Biotech Research is unable to ensure such a supply.

 

Pursuant to the Agreement, certain customary events of default, such as the Company’s or Edesa Biotech Research’s breach of their covenants and obligations under the Agreement, their insolvency, winding up or dissolution, and other similar events, may permit the Government of Canada to declare an event of default under the Agreement. Upon an event of default, subject to applicable cure, the Government of Canada may exercise a number of remedies, including suspending or terminating funding under the Agreement, demanding repayment of funding previously received and/or terminating the Agreement.

 

The funding and any associated conditional repayments are not secured by any assets of Edesa Biotech Research or the Company.

 

The Agreement will expire on the later of December 31, 2042 or the date of the last repayment, unless earlier terminated, subject to certain provisions that extend three (3) years beyond the term or early termination of the Agreement.

 

 

 

 

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which will be filed with the Company’s annual report on Form 10-K for the fiscal year ending September 30, 2023.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

The information set forth under Items 1.01 and 8.01 is incorporated into this Item 2.03 by reference.

 

Item 7.01 Regulation FD Disclosure

 

On October 12, 2023, the Company issued a press release announcing the execution of the Agreement. The full text of the press release is attached hereto as Exhibit 99.1.

 

On October 12, 2023, the Company issued a press release announcing that it has entered into a binding commitment letter with Dr. Par Nijhawan, MD, the Company’s Chief Executive Officer and member of the Board of Directors of the Company related to a $10 million revolving credit facility agreement. The full text of the press release is attached hereto as Exhibit 99.2.

 

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

 

Item 8.01 Other Events

 

On October 12, 2023, the Company announced that it has entered into a binding commitment letter with Dr. Par Nijhawan, MD, the Company’s Chief Executive Officer and member of the Board of Directors of the Company related to a $10 million revolving credit facility agreement. The binding commitment letter provides for a revolving line of credit in the amount of up to $10 million, with $3.5 million available immediately upon the execution of the definitive agreement for the credit facility. Advances under the revolving credit facility will be subject to compliance with all applicable laws, and tied to a borrowing base consisting of eligible grant reimbursement receivables, future potential license fee receivables and any other accounts receivable. The binding commitment letter provides for an interest rate of the CIBC US Base-Interest Rate plus 300bps and a maturity date of March 31, 2026. The availability of the credit facility will be subject to finalization and execution of a definitive credit agreement and related documents.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release, dated October 12, 2023.
99.2   Press Release, dated October 12, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Edesa Biotech, Inc.
   
Date: October 12, 2023 By: /s/ Stephen Lemieux
  Name: Stephen Lemieux
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2328265d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

 

TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company’s first-in-class therapeutic candidate.

 

Edesa’s experimental drug, called EB05 (paridiprubart), represents a new class of emerging therapies called Host-Directed Therapeutics (HDTs) that are designed to modulate the body's own immune response when confronted with infectious diseases or even chemical agents. Importantly, these therapies are agnostic to the causal agent and can be stockpiled preemptively for seasonal outbreaks and unexpected emergencies and threats.

 

“This project has the potential to increase survival rates, reduce ICU costs and improve outcomes for critically ill patients,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “With this validation and the continued support from the federal government, we believe we are in a position to accelerate research, expand our reach to more hospitals and move another significant step closer to commercialization.”

 

Edesa’s current project builds on the success of a government-supported Phase 2 clinical study completed during the pandemic which demonstrated that paridiprubart reduced mortality by 84% among critically ill patients with a severe form of respiratory disease called Acute Respiratory Distress Syndrome (ARDS). A parallel in vitro study at the University of Toronto also demonstrated recently that paridiprubart inhibits inflammation from influenza and other pathogens.

 

“We are proud of our track record of delivering successful results on time and on budget for our government-supported projects,” said Dr. Nijhawan. “The development of breakthrough medicines – especially in the critical care fields – is key to building a strong biopharma sector, creating jobs and most importantly improving patient outcomes at home and abroad. We are honored to be a part of these efforts.”

 

The Honorable François-Philippe Champagne, Minister of Innovation, Science and Industry said that the Strategic Innovation Fund (SIF) funding announced today is part of the government's plan to grow a strong and competitive life sciences sector, and ensure the nation’s readiness for future pandemics or other health emergencies.

 

“This project is a prime example of Canada's determination to the development of the next generation of medicine, while creating good jobs and securing long-term economic growth,” said Minister Champagne.

 

Edesa intends to use the SIF funding toward study expenses, including hospital and physician expenditures, as well as scale-up of commercial drug product should the development program be successful. Funding is provided under the federal government’s Strategic Innovation Fund (SIF) following a competitive review process.

 

Additional information regarding the funding are outlined in the company’s Current Report on Form 8-K, which Edesa expects to file with the U.S. Securities and Exchange Commission and on the SEDAR+ system in Canada.

 

 

 

 

About ARDS

 

ARDS involves an exaggerated immune response leading to inflammation and injury to the lungs that prevents the lungs from oxygenating blood and ultimately deprives the body of oxygen. For moderate to severe cases, there are currently few meaningful treatments, other than supplemental oxygen and mechanical ventilation, and patients suffer high mortality rates. In addition to virus-induced pneumonia, ARDS can be caused by smoke/chemical inhalation, sepsis, chest injury and other causes. Prior to the pandemic, ARDS accounted for 10% of intensive care unit admissions, representing more than 3 million patients globally each year.

 

About EB05 (Paridiprubart)

 

Paridiprubart is a first-in-class monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. This host-directed therapeutic (HDT) candidate inhibits toll-like receptor 4 (TLR4), a key immune signaling protein that has been shown to be activated both by viruses, like SARS-CoV2, SARS-CoV1 and Influenza, as well as in the pathogenesis of chronic autoimmune diseases.

 

About Phase 3 Clinical Study

 

Edesa’s Phase 3 study of EB05 (paridiprubart) is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EB05 in critical-care patients. The current protocol calls for treatment of ARDS subjects hospitalized with SARS-CoV2 infections who are on invasive mechanical ventilation, both with and without additional organ support. The primary endpoint is the mortality rate at 28 days. In addition to SARS-CoV2 induced ARDS, Edesa is currently exploring various approaches to evaluate EB05 in a general ARDS population.

 

About Edesa Biotech, Inc.

 

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The Company’s most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The Company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. Edesa is also planning to file an investigational new drug application for a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis, (scarring/hardening) of skin and internal organs such as the lungs, heart and kidneys. Sign up for news alerts. Connect with us on Twitter and LinkedIn.

 

 

 

 

Edesa Forward-Looking Statements

 

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as Covid-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

 

Contact
Gary Koppenjan
Edesa Biotech, Inc.
(289) 800-9600
investors@edesabiotech.com

 

 

 

 EX-99.2 3 tm2328265d1_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

 

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

 

·Revolving Line of Credit to Support Completion of Government-Funded ARDS Study

 

TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA) (“Edesa”, or the “Company”), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced it has entered into a binding commitment letter in respect of a $10 million revolving credit facility agreement with Dr. Par Nijhawan, MD, the Company’s Chief Executive Officer and Founder. The binding commitment letter was executed in parallel with a C$23 million commitment from the Government of Canada to support a pivotal Phase 3 clinical study of the Company’s first-in-class therapeutic candidate.

 

Stephen Lemieux, Chief Financial Officer of the Company, said that the credit facility will be an important part of the Company’s growth strategy, and in particular, its development and commercialization plans for EB05 (paridiprubart), a monoclonal antibody that Edesa is developing as a treatment for a severe form of respiratory failure known as Acute Respiratory Distress Syndrome (ARDS).

 

“We greatly appreciate this vote of confidence from our Founder, and the attractive terms of the agreement,” said Mr. Lemieux. “With this financial milestone and the funding commitment from the Government of Canada, we will be in a significantly stronger position to move forward toward the completion of our pivotal Phase 3 study of EB05 and prepare for potential approval.”

 

The binding commitment letter with Dr. Nijhawan provides for a revolving line of credit in the amount of up to $10 million, with $3.5 million available immediately upon the execution of the definitive agreement for the credit facility. Advances under the revolving credit facility will be subject to compliance with all applicable laws, and tied to a borrowing base consisting of eligible grant reimbursement receivables, future potential license fee receivables and any other accounts receivable. The binding commitment letter provides for an interest rate of the CIBC US Base-Interest Rate plus 300 bps and a maturity date of March 31, 2026. The availability of the credit facility will be subject to finalization and execution of a definitive credit agreement and related documents.

 

“I’m pleased to provide both financial support and leadership to the company as it builds on its recent operational and clinical successes,” said Dr. Nijhawan. “Edesa has a strong development pipeline and I’m confident that we can continue to successfully execute on our plans to commercialize innovative drug therapies for large, underserved patient populations.”

 

Additional details on the revolving credit facility will be outlined in the Company’s Current Report on Form 8-K, which the Company expects to file with the U.S. Securities and Exchange Commission and on the SEDAR+ system in Canada.

 

The entering into of the binding commitment letter with respect to the credit facility constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions. The Company will file a material change report less than 21 days before the credit facility will be entered into, which shorter period is necessary in the circumstances in order for the Company to access working capital in the short term to continue its development and commercialization plans.

 

 

 

 

About Edesa Biotech, Inc.

 

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The Company’s most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The Company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. Edesa is also planning to file an investigational new drug application for a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis, (scarring/hardening) of skin and internal organs such as the lungs, heart and kidneys. Sign up for news alerts. Connect with us on Twitter and LinkedIn.

 

Edesa Forward-Looking Statements


This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to finalize and execute the definitive credit agreement related to the $10 million credit facility, the final terms of the credit facility, the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as Covid-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

 

Contact
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800
investors@edesabiotech.com

 

 

 

 EX-101.SCH 4 edsa-20231012.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 edsa-20231012_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 edsa-20231012_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2328265d1_ex99-1img01.jpg GRAPHIC begin 644 tm2328265d1_ex99-1img01.jpg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tm2328265d1_ex99-2img01.jpg GRAPHIC begin 644 tm2328265d1_ex99-2img01.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 12, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 12, 2023
Entity File Number 001-37619
Entity Registrant Name Edesa Biotech, Inc.
Entity Central Index Key 0001540159
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One 100 Spy Court
Entity Address, City or Town Markham
Entity Address, State or Province ON
Entity Address, Country CA
Entity Address, Postal Zip Code L3R 5H6
City Area Code 289
Local Phone Number 800-9600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares
Trading Symbol EDSA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 tm2328265d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001540159 2023-10-12 2023-10-12 iso4217:USD shares iso4217:USD shares 0001540159 false 00-0000000 8-K 2023-10-12 Edesa Biotech, Inc. A1 001-37619 100 Spy Court Markham ON CA L3R 5H6 289 800-9600 false false false false Common Shares EDSA NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://edesabiotech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports edsa-20231012.xsd edsa-20231012_lab.xml edsa-20231012_pre.xml tm2328265d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2328265d1_8k.htm": { "nsprefix": "edsa", "nsuri": "http://edesabiotech.com/20231012", "dts": { "schema": { "local": [ "edsa-20231012.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "edsa-20231012_lab.xml" ] }, "presentationLink": { "local": [ "edsa-20231012_pre.xml" ] }, "inline": { "local": [ "tm2328265d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://edesabiotech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2328265d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2328265d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://edesabiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001104659-23-108762-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-108762-xbrl.zip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